An observational study in Multiple Sclerosis and Gait Disorders, Neurologic, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Multiple Sclerosis by Assiut University — 15 open to participants now, 15 under way, none of them phase 3. Multiple Sclerosis · Assiut University.
Among the 26 studies in Multiple Sclerosis by Assiut University, this one is the 15th largest by planned enrollment of the 24 observational ones that give a count, is one of 6 that started in 2026, is one of 24 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 25th registered.
3,269 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →15 of the 26 studies in Multiple Sclerosis by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18–49 · Women only
Assiut University
Ages 20–50 · Healthy volunteers
Assiut University
Ages 18+
Assiut University
Ages 18–55
Assiut University · Sites in Egypt
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 6 started in 2026.
This study's planned enrollment of 70 is below the median of 100 across 971 observational studies indexed under Multiple Sclerosis.
Median enrollment 48 across the 2 interventional studies, 100 across the 24 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Multiple Sclerosis by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06770959Assiut UniversityFrequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study | 2026-12 |
| NCT06017726Assiut UniversityInsulin Resistance in Egyptian Patients With Multiple Sclerosis | 2026-12 |
| NCT07847086Assiut UniversityGait Pattern and Its Relation to Cognition and VEP in Multiple Sclerosis | 2027-09-26 |
| NCT07846943Assiut UniversityEpstein-Barr Virus Antibodies in Egyptian Patients With Multiple Sclerosis | 2027-10 |
| NCT07826221Assiut UniversityPrevalence of Primary Headache in Multiple Sclerosis Patients | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies in Multiple Sclerosis by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cross-sectional study aims to assess the pattern of gait in patients with multiple sclerosis and to evaluate its relation to cognitive function, visual evoked potentials, and radiological findings.
Gait impairment is a common and disabling feature of multiple sclerosis. This observational study will include patients with confirmed multiple sclerosis according to the revised McDonald criteria who are clinically stable.
Participants will undergo quantitative gait analysis, cognitive assessment, visual evoked potential testing, and review of MRI findings in a single assessment visit.
Patients with multiple sclerosis attending the Neurology Department outpatient clinic and gait laboratory at Assiut University.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with confirmed multiple sclerosis who will undergo gait analysis, cognitive testing, visual evoked potential assessment, and MRI review in a single visit.
Mean gait velocity
Mean gait velocity in meters per second measured by quantitative spatiotemporal gait analysis.
Time frame: Baseline
Mean cadence
Mean cadence in steps per minute measured by quantitative gait analysis.
Time frame: Baseline
Mean stride length
Mean stride length in centimeters measured by quantitative gait analysis.
Time frame: Baseline
Mean MoCA score
Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition).
Time frame: Baseline
Mean P100 latency
Mean P100 latency in milliseconds measured by pattern-reversal visual evoked potentials.
Time frame: Baseline
Mean EDSS score
Mean Expanded Disability Status Scale (EDSS) score (range 0-10, higher scores indicate worse disability).
Time frame: Baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.